{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:44:09Z","timestamp":1785789849643,"version":"3.56.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ibroneuroreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IBRO Neuroscience Reports"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ibneur.2023.01.009","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T03:10:51Z","timestamp":1675048251000},"page":"146-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Gene therapy for selected neuromuscular and trinucleotide repeat disorders \u2013 An insight to subsume South Asia for multicenter clinical trials"],"prefix":"10.1016","volume":"14","author":[{"given":"Nalaka","family":"Wijekoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakmal","family":"Gonawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pyara","family":"Ratnayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshana","family":"Sirisena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha","family":"Gunasekara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athula","family":"Dissanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunethra","family":"Senanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajantha","family":"Keshavaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetrib","family":"Hathout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry W.M.","family":"Steinbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5929-745X","authenticated-orcid":false,"given":"Ashwin","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.Ranil","family":"D de Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ibneur.2023.01.009_bib1","first-page":"363","article-title":"Rethinking community based strategies to tackle health inequities in South Asia","author":"Bhutta","year":"2018","journal-title":"Bmj"},{"key":"10.1016\/j.ibneur.2023.01.009_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.608249","article-title":"Development and use of gene therapy orphan drugs\u2014ethical needs for a broader cooperation between the pharmaceutical industry and society","volume":"7","author":"Kerpel-Fronius","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.ibneur.2023.01.009_bib3","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fgene.2019.00868","article-title":"Development and clinical translation of approved gene therapy products for genetic disorders","volume":"10","author":"Shahryari","year":"2019","journal-title":"Front. Genet."},{"issue":"17","key":"10.1016\/j.ibneur.2023.01.009_bib4","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: first global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ibneur.2023.01.009_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: first approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ibneur.2023.01.009_bib6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.ibneur.2023.01.009_bib7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: first approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ibneur.2023.01.009_bib8","first-page":"1","article-title":"Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination","volume":"13","author":"Huang","year":"2022","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ibneur.2023.01.009_bib9","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.ibneur.2023.01.009_bib10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ibneur.2023.01.009_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107719","article-title":"Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy","volume":"220","author":"Iftikhar","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ibneur.2023.01.009_bib12","doi-asserted-by":"crossref","unstructured":"Kwon J.M., Arya K., Kuntz N., Phan H.C., Sieburg C., Swoboda K.J., et al. An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy. Annals of Clinical and Translational Neurology. 2022.","DOI":"10.1002\/acn3.51560"},{"issue":"3","key":"10.1016\/j.ibneur.2023.01.009_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/ijabmr.IJABMR_190_19","article-title":"Onasemnogene abeparvovec for spinal muscular atrophy: the costlier drug ever","volume":"9","author":"Mahajan","year":"2019","journal-title":"Int. J. Appl. Basic Med. Res."},{"issue":"2","key":"10.1016\/j.ibneur.2023.01.009_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/brainsci11020129","article-title":"Intrastriatal Administration of AAV5-miHTT in non-human primates and rats is well tolerated and results in miHTT transgene expression in key areas of Huntington disease pathology","volume":"11","author":"Spronck","year":"2021","journal-title":"Brain Sci."},{"issue":"16","key":"10.1016\/j.ibneur.2023.01.009_bib15","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.3390\/ijms22168363","article-title":"New avenues for the treatment of Huntington\u2019s disease","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ibneur.2023.01.009_bib16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ymthe.2018.02.002","article-title":"Translation of microRNA-based huntingtin-lowering therapies from preclinical studies to the clinic","volume":"26","author":"Miniarikova","year":"2018","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ibneur.2023.01.009_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14802\/jmd.21006","article-title":"Gene therapy for huntington\u2019s disease: the final strategy for a cure","volume":"15","author":"Byun","year":"2022","journal-title":"J. Mov. Disord."},{"issue":"1","key":"10.1016\/j.ibneur.2023.01.009_bib18","first-page":"1","article-title":"The genetic legacy of continental scale admixture in Indian Austroasiatic speakers","volume":"9","author":"T\u00e4tte","year":"2019","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ibneur.2023.01.009_bib19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1017\/S0021932018000275","article-title":"Estimating the health and socioeconomic effects of cousin marriage in South Asia","volume":"51","author":"Mobarak","year":"2019","journal-title":"J. Biosoc. Sci."},{"issue":"4","key":"10.1016\/j.ibneur.2023.01.009_bib20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1017\/S0021932019000658","article-title":"Marriage patterns in Sri Lanka and the prevalence of parental consanguinity in patients with \u03b2-thalassaemia: a cross-sectional descriptive analysis","volume":"52","author":"Premawardhena","year":"2020","journal-title":"J. Biosoc. Sci."},{"issue":"11","key":"10.1016\/j.ibneur.2023.01.009_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241610","article-title":"Genetic and reproductive consequences of consanguineous marriage in Bangladesh","volume":"15","author":"Anwar","year":"2020","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.ibneur.2023.01.009_bib22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.gene.2014.12.023","article-title":"Trend of different molecular markers in the last decades for studying human migrations","volume":"556","author":"Kundu","year":"2015","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.ibneur.2023.01.009_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/jhg.2013.112","article-title":"Mitochondrial DNA history of Sri Lankan ethnic people: their relations within the island and with the Indian subcontinental populations","volume":"59","author":"Ranaweera","year":"2014","journal-title":"J. Hum. Genet."},{"issue":"6","key":"10.1016\/j.ibneur.2023.01.009_bib24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.nmd.2010.04.005","article-title":"Best practice guidelines on molecular diagnostics in Duchenne\/Becker muscular dystrophies","volume":"20","author":"Abbs","year":"2010","journal-title":"Neuromuscul. Disord."},{"issue":"9","key":"10.1016\/j.ibneur.2023.01.009_bib25","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41431-020-0643-7","article-title":"EMQN best practice guidelines for genetic testing in dystrophinopathies","volume":"28","author":"Fratter","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ibneur.2023.01.009_bib26","unstructured":"Prior T., Leach M., Finanger E. Spinal muscular atrophy. 2000. GeneReviews (R)[Internet] Seattle (WA): University of Washington, Seattle. 2020."},{"issue":"2","key":"10.1016\/j.ibneur.2023.01.009_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul. Disord."},{"issue":"11","key":"10.1016\/j.ibneur.2023.01.009_bib28","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/ejhg.2010.8","article-title":"EMQN best practice guidelines for molecular genetic testing of SCAs","volume":"18","author":"Sequeiros","year":"2010","journal-title":"Eur. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.ibneur.2023.01.009_bib29","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/ejhg.2012.200","article-title":"EMQN\/CMGS best practice guidelines for the molecular genetic testing of Huntington disease","volume":"21","author":"Losekoot","year":"2013","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ibneur.2023.01.009_bib30","unstructured":"Medicine TJoG. Gene Theraphy clinical trials Worldwide 2021 [Available from: https:\/\/a873679.fmphost.com\/fmi\/webd\/GTCT."},{"issue":"7","key":"10.1016\/j.ibneur.2023.01.009_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12098-020-03286-z","article-title":"Mutation spectrum of dystrophinopathies in India: Implications for therapy","volume":"87","author":"Kohli","year":"2020","journal-title":"Indian J. Pediatr."},{"issue":"6","key":"10.1016\/j.ibneur.2023.01.009_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232654","article-title":"Comprehensive genetic analysis of 961 unrelated Duchenne Muscular Dystrophy patients: Focus on diagnosis, prevention and therapeutic possibilities","volume":"15","author":"Kumar","year":"2020","journal-title":"Plos One"},{"issue":"7","key":"10.1016\/j.ibneur.2023.01.009_bib33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1089\/gtmb.2018.0262","article-title":"MLPA analyses reveal a spectrum of dystrophin gene deletions\/duplications in Pakistani patients suspected of having Duchenne\/Becker muscular dystrophy: a retrospective study","volume":"23","author":"Ansar","year":"2019","journal-title":"Genet. Test. Mol. Biomark."},{"issue":"2","key":"10.1016\/j.ibneur.2023.01.009_bib34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/aian.AIAN_505_19","article-title":"Clinical profile of genetically proven huntington's disease patients from Eastern India","volume":"23","author":"Hussain","year":"2020","journal-title":"Ann. Indian Acad. Neurol."},{"issue":"3","key":"10.1016\/j.ibneur.2023.01.009_bib35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4103\/0028-3886.43454","article-title":"Deletion analysis of spinal muscular atrophy in southern Indian population","volume":"56","author":"Swaminathan","year":"2008","journal-title":"Neurol. India"},{"issue":"3","key":"10.1016\/j.ibneur.2023.01.009_bib36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/emm.2005.20","article-title":"Genotype-phenotype correlation of SMN locus genes in spinal muscular atrophy patients from India","volume":"37","author":"Kesari","year":"2005","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.ibneur.2023.01.009_bib37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4103\/0028-3886.98514","article-title":"Spinal muscular atrophy: Clinical spectrum and genetic mutations in Pakistani children","volume":"60","author":"Ibrahim","year":"2012","journal-title":"Neurol. India"},{"key":"10.1016\/j.ibneur.2023.01.009_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2022.04.002","article-title":"Gene therapy access: global challenges, opportunities and views from Brazil, South africa, and India","author":"Cornetta","year":"2022","journal-title":"Mol. Ther."},{"issue":"3\u20134","key":"10.1016\/j.ibneur.2023.01.009_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/0972753120950069","article-title":"What we fail to see in neuro-genetic diseases: a bird\u2019s eye view from the developing world","volume":"27","author":"Samaranayake","year":"2020","journal-title":"Ann. Neurosci."},{"issue":"12","key":"10.1016\/j.ibneur.2023.01.009_bib40","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S1474-4422(20)30405-1","article-title":"A biobank in Sri Lanka that links East and West","volume":"19","author":"Wijekoon","year":"2020","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.ibneur.2023.01.009_bib41","doi-asserted-by":"crossref","first-page":"721","DOI":"10.4103\/jfmpc.jfmpc_50_17","article-title":"Enabling the disabled: call for intercepting disability surge in Pakistan","volume":"6","author":"Naseem","year":"2017","journal-title":"J. Fam. Med. Prim. Care"},{"issue":"03","key":"10.1016\/j.ibneur.2023.01.009_bib42","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1055\/s-0040-1713301","article-title":"Diagnosing muscular dystrophies: comparison of techniques and their cost effectiveness: a multi-institutional study","volume":"11","author":"Srivastava","year":"2020","journal-title":"J. Neurosci. Rural Pract."},{"issue":"3","key":"10.1016\/j.ibneur.2023.01.009_bib43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense\u2010mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma\u2010Rus","year":"2009","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.ibneur.2023.01.009_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/iju.IJU_372_18","article-title":"IJU for the Indian subcontinent","volume":"35","author":"Kumar","year":"2019","journal-title":"Indian J. Urol.: IJU: J. Urol. Soc. India"},{"issue":"1","key":"10.1016\/j.ibneur.2023.01.009_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2217\/cer-2017-0068","article-title":"Gene therapy: evidence, value and affordability in the US health care system","volume":"7","author":"Hampson","year":"2018","journal-title":"J. Comp. Eff. Res."},{"issue":"4","key":"10.1016\/j.ibneur.2023.01.009_bib46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2217\/rme-2016-0010","article-title":"Gene therapies: the challenge of super-high-cost treatments and how to pay for them","volume":"11","author":"Carr","year":"2016","journal-title":"Regen. Med."},{"issue":"2","key":"10.1016\/j.ibneur.2023.01.009_bib47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jcyt.2016.10.017","article-title":"The path to successful commercialization of cell and gene therapies: empowering patient advocates","volume":"19","author":"Bauer","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ibneur.2023.01.009_bib48","unstructured":"research Am. Gene Therapy Market by Vector Type (Viral Vector, Non Viral Vector), by Therapy (In Vivo Therapy, Ex Vivo Therapy), by Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth factors, Receptors, Others), by Application (Oncological Disorders, Rare Diseases, Neurological Disorders, Other Diseases): Global Opportunity Analysis and Industry Forecast, 2020\u20132030: Allied market research; 2022 [Available from: https:\/\/www.alliedmarketresearch.com\/gene-therapy-market."},{"issue":"1","key":"10.1016\/j.ibneur.2023.01.009_bib49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41587-021-01191-0","article-title":"Expanding global access to genetic therapies","volume":"40","author":"Muigai","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ibneur.2023.01.009_bib50","first-page":"845","article-title":"In this month\u2019s Bulletin","volume":"99","author":"Ekstr\u00f6m","year":"2021","journal-title":"Bull. World Health Organ"},{"key":"10.1016\/j.ibneur.2023.01.009_bib51","series-title":"Waive Covid vaccine patents to put world on war footing","author":"Ghebreyesus","year":"2021"},{"issue":"7","key":"10.1016\/j.ibneur.2023.01.009_bib52","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/acn3.51370","article-title":"Spinocerebellar ataxia clinical trials: opportunities and challenges","volume":"8","author":"Brooker","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.ibneur.2023.01.009_bib53","first-page":"179","article-title":"Optimizing exon skipping therapies for DMD","volume":"26","author":"Yokota","year":"2007","journal-title":"Acta Myol."},{"issue":"1","key":"10.1016\/j.ibneur.2023.01.009_bib54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/nat.2013.0451","article-title":"Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides","volume":"24","author":"Echigoya","year":"2014","journal-title":"Nucleic Acid. Ther."},{"issue":"2","key":"10.1016\/j.ibneur.2023.01.009_bib55","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/humu.20422","article-title":"Protein\u2010and mRNA\u2010based phenotype\u2013genotype correlations in DMD\/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene","volume":"28","author":"Deburgrave","year":"2007","journal-title":"Hum. Mutat."},{"issue":"20","key":"10.1016\/j.ibneur.2023.01.009_bib56","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1093\/hmg\/ddp320","article-title":"Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression","volume":"18","author":"Daoud","year":"2009","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.ibneur.2023.01.009_bib57","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT\u2010NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"issue":"14","key":"10.1016\/j.ibneur.2023.01.009_bib58","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jama.2013.1468","article-title":"Accessing genomic medicine: affordability, diffusion, and disparities","volume":"309","author":"Tuckson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ibneur.2023.01.009_bib59","series-title":"Seminars in Oncology Nursing","article-title":"Nursing implications of personalized and precision medicine","author":"Vorderstrasse","year":"2014"},{"key":"10.1016\/j.ibneur.2023.01.009_bib60","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ejca.2017.07.028","article-title":"Societal challenges of precision medicine: bringing order to chaos","volume":"84","author":"Salgado","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.ibneur.2023.01.009_bib61","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1007\/s12325-017-0587-7","article-title":"Patient perspectives on gene transfer therapy for sickle cell disease","volume":"34","author":"Strong","year":"2017","journal-title":"Adv. Ther."}],"container-title":["IBRO Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266724212300009X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266724212300009X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T08:10:04Z","timestamp":1757405404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266724212300009X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":61,"alternative-id":["S266724212300009X"],"URL":"https:\/\/doi.org\/10.1016\/j.ibneur.2023.01.009","relation":{},"ISSN":["2667-2421"],"issn-type":[{"value":"2667-2421","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for selected neuromuscular and trinucleotide repeat disorders \u2013 An insight to subsume South Asia for multicenter clinical trials","name":"articletitle","label":"Article Title"},{"value":"IBRO Neuroscience Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ibneur.2023.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of International Brain Research Organization.","name":"copyright","label":"Copyright"}]}}